ANAB AnaptysBio Inc.

54.84
-0.82  -1%
Previous Close 55.66
Open 55.73
Price To Book 3.17
Market Cap 1,481,981,079
Shares 27,023,725
Volume 9,792
Short Ratio
Av. Daily Volume 303,396

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 2H 2019.
ANB020 - etokimab
Moderate-to-severe adult atopic dermatitis
Phase 2b trial to be initiated 2019.
ANB020 - etokimab
Severe adult eosinophilic asthma
Phase 2 data due 1H 2020.
ANB019
Palmo-plantar pustular psoriasis
Phase 2 data due mid-2019.
ANB019
Generalized pustular psoriasis
Phase 2 data due 2H 2019.
ANB020 - etokimab
Nasal polyps

Latest News

  1. Regeneron And Sanofi Tried To Outperform Themselves — And Couldn't
  2. Here's Why AnaptysBio Shares Are Sliding Today
  3. Does The AnaptysBio, Inc. (NASDAQ:ANAB) Share Price Tend To Follow The Market?
  4. Does AnaptysBio, Inc. (NASDAQ:ANAB) Have A Volatile Share Price?
  5. AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma
  6. AnaptysBio to Present at the Jefferies 2019 Healthcare Conference
  7. AnaptysBio Started 2019 Quiet as a Ninja
  8. AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates
  9. Is AnaptysBio, Inc. (ANAB) A Good Stock To Buy?
  10. AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference
  11. What Makes AnaptysBio, Inc. (ANAB) a New Strong Buy Stock
  12. Will AnaptysBio Continue to Surge Higher?
  13. Introducing AnaptysBio (NASDAQ:ANAB), The Stock That Dropped 42% In The Last Year
  14. All You Need to Know About AnaptysBio, Inc. (ANAB) Rating Upgrade to Buy
  15. AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference
  16. AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates
  17. AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference
  18. Hedge Funds Are Crazy About AnaptysBio, Inc. (ANAB)
  19. Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  20. Here's Why AnaptysBio, Inc. Slipped on Friday